Currently, interest in the therapeutic applications of psychedelics has expanded, with ibogaine, an atypical psychedelic derived from the root of Tabernanthe iboga, emerging as a promising candidate. Although acute ibogaine administration has been reported to induce antidepressant-like effects in male rodents, its potential in female rats remains unexplored. This knowledge gap is particularly relevant because ovarian hormones influence numerous neurotransmission systems implicated in the action of psychedelic drugs. The present study evaluated the hypothesis that ibogaine exerts an antidepressant-like effect in female rats, and that its intensity varies according to the estrous cycle phase. Adult female Wistar rats received a single intraperitoneal dose of ibogaine (40 mg/kg) or vehicle during either proestrus or metestrus, characterized by high and low plasma estrogen levels, respectively. Four hours after administration, animals were assessed in the forced swimming test. Ibogaine induced a decrease in immobility time across both phases, while an increase in swimming behavior was observed exclusively in metestrus females. These results indicate that ibogaine produces an antidepressant-like effect in female rats, with behavioral outcomes that vary depending on the estrous cycle phase, highlighting the modulatory role of the endocrine environment in shaping the response to this psychedelic compound.